Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and γc overexpression

Molecular Therapy

Volumn 18, Issue 5, 2010, Pages 965-976

  Ginn, Samantha L ^a   Liao, Sophia Hy ^a   Dane, Allison P ^a   Hu, Min ^b   Hyman, Jessica ^b   Finnie, John W ^c   Zheng, Maolin ^a   Cavazzana Calvo, Marina ^d   Alexander, Stephen I ^b   Thrasher, Adrian J ^e   Alexander, Ian E ^a,f  

^a CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ELONGATION FACTOR 1ALPHA; INTERLEUKIN 2 RECEPTOR GAMMA; LENTIVIRUS VECTOR; PHOSPHOGLYCERATE KINASE; WISKOTT ALDRICH SYNDROME PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CARCINOGENESIS; CELL MATURATION; GENE INSERTION; GENE OVEREXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOMA; MOUSE; MUTAGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; SCID MOUSE; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE THERAPY; GENETIC VECTORS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LENTIVIRUS; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, SCID; MUTAGENESIS, INSERTIONAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; X-LINKED COMBINED IMMUNODEFICIENCY DISEASES;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; MUS;

EID: 77952009127     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.50     Document Type: Article

References (51)

1. Sugamura, K, Asao, H, Kondo, M, Tanaka, N, Ishii, N, Nakamura, M et al. (1995). The common gamma-chain for multiple cytokine receptors. Adv Immunol 59:225-277.
2. Asao, H, Okuyama, C, Kumaki, S, Ishii, N, Tsuchiya, S, Foster, D et al. (2001). Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 167:1-5.
3. Noguchi, M, Nakamura, Y, Russell, SM, Ziegler, SF, Tsang, M, Cao, X et al. (1993). Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science 262:1877-1880. (Pubitemid 24041859)
4. Buckley, RH, Schiff, RI, Schiff, SE, Markert, ML, Williams, LW, Harville, TO et al. (1997). Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 130:378-387.
5. Cavazzana-Calvo, M, Hacein-Bey, S, de Saint Basile, G, De Coene, C, Selz, F, Le Deist, F et al. (1996). Role of interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from gamma c transduced severe combined immunodeficiency X1 bone marrow cells. Blood 88:3901-3909.
6. Puel, A, Ziegler, SF, Buckley, RH and Leonard, WJ (1998). Defective IL7R expression in T (-) B (+) NK (+) severe combined immunodeficiency. Nat Genet 20:394-397.
7. Buckley, RH, Schiff, SE, Schiff, RI, Markert, L, Williams, LW, Roberts, JL et al. (1999). Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 340:508-516.
8. Antoine, C, Müller, S, Cant, A, Cavazzana-Calvo, M, Veys, P, Vossen, J et al.; European Group for Blood and Marrow Transplantation; European Society for Immunodeficiency. (2003). Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 361:553-560.
9. Cavazzana-Calvo, M, Hacein-Bey, S, de Saint Basile, G, Gross, F, Yvon, E, Nusbaum, P et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669-672. (Pubitemid 30241569)
10. Hacein-Bey-Abina, S, Le Deist, F, Carlier, F, Bouneaud, C, Hue, C, De Villartay, JP et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346:1185-1193. (Pubitemid 34984579)
11. Gaspar, HB, Parsley, KL, Howe, S, King, D, Gilmour, KC, Sinclair, J et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364:2181-2187.
12. Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118:3132-3142.
13. Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118:3143-3150.
14. Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12:401-409.
15. De Palma, M, Montini, E, Santoni de Sio, FR, Benedicenti, F, Gentile, A, Medico, E et al. (2005). Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105:2307-2315.
16. Thornhill, SI, Schambach, A, Howe, SJ, Ulaganathan, M, Grassman, E, Williams, D et al. (2008). Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther 16:590-598.
17. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Bartholomae, CC, Ranzani, M et al. (2009). The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119:964-975.
18. Smyth, CM, Ginn, SL, Deakin, CT, Logan, GJ and Alexander, IE (2007). Limiting {gamma}c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors. Blood 110:91-98.
19. Li, Z, Schwieger, M, Lange, C, Kraunus, J, Sun, H, van den Akker, E et al. (2003). Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp Hematol 31:1206-1214.
20. Kustikova, OS, Wahlers, A, Kuhlcke, K, Stahle, B, Zander, AR, Baum, C et al. (2003). Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 102:3934-3937.
21. Woods, NB, Bottero, V, Schmidt, M, von Kalle, C and Verma, IM (2006). Gene therapy: therapeutic gene causing lymphoma. Nature 440:1123.
22. Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Ponzoni, M, Bartholomae, C et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24:687-696.
23. Shou, Y, Ma, Z, Lu, T and Sorrentino, BP (2006). Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci USA 103:11730-11735.
24. Siapati, EK, Bigger, BW, Kashofer, K, Themis, M, Thrasher, AJ and Bonnet, D (2007). Murine leukemia following irradiation conditioning for transplantation of lentivirally-modified hematopoietic stem cells. Eur J Haematol 78:303-313.
25. Follenzi, A, Ailles, LE, Bakovic, S, Geuna, M and Naldini, L (2000). Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25:217-222.
26. Karlsson, A, Ungerbäck, J, Rasmussen, A, French, JE and Söderkvist, P (2008). Notch1 is a frequent mutational target in chemically induced lymphoma in mouse. Int J Cancer 123:2720-2724.
27. O'Neil, J, Calvo, J, McKenna, K, Krishnamoorthy, V, Aster, JC, Bassing, CH et al. (2006). Activating Notch1 mutations in mouse models of T-ALL. Blood 107:781-785.
28. Ramezani, A, Hawley, TS and Hawley, RG (2000). Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol Ther 2:458-469.
29. Benhamida, S, Pflumio, F, Dubart-Kupperschmitt, A, Zhao-Emonet, JC, Cavazzana-Calvo, M, Rocchiccioli, F et al. (2003). Transduced CD34+ cells from adrenoleukodystrophy patients with HIV-derived vector mediate long-term engraftment of NOD/SCID mice. Mol Ther 7:317-324.
30. Zychlinski, D, Schambach, A, Modlich, U, Maetzig, T, Meyer, J, Grassman, E et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther 16:718-725.
31. Hendrie, PC, Huo, Y, Stolitenko, RB and Russell, DW (2008). A rapid and quantitative assay for measuring neighboring gene activation by vector proviruses. Mol Ther 16:534-540.
32. Robert-Richard, E, Richard, E, Malik, P, Ged, C, de Verneuil, H and Moreau-Gaudry, F (2007). Murine retroviral but not human cellular promoters induce in vivo erythroid-specific deregulation that can be partially prevented by insulators. Mol Ther 15:173-182.
33. Schambach, A, Bohne, J, Chandra, S, Will, E, Margison, GP, Williams, DA et al. (2006). Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther 13:391-400.
34. Benjelloun, F, Garrigue, A, Demerens-de Chappedelaine, C, Soulas-Sprauel, P, Malassis-Séris, M, Stockholm, D et al. (2008). Stable and functional lymphoid reconstitution in artemis-deficient mice following lentiviral artemis gene transfer into hematopoietic stem cells. Mol Ther 16:1490-1499.
35. Will, E, Bailey, J, Schuesler, T, Modlich, U, Balcik, B, Burzynski, B et al. (2007). Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials. Mol Ther 15:782-791.
36. Mortellaro, A, Hernandez, RJ, Guerrini, MM, Carlucci, F, Tabucchi, A, Ponzoni, M et al. (2006). Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood 108:2979-2988.
37. Hargrove, PW, Kepes, S, Hanawa, H, Obenauer, JC, Pei, D, Cheng, C et al. (2008). Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. Mol Ther 16:525-533.
38. Pike-Overzet, K, de Ridder, D, Weerkamp, F, Baert, MR, Verstegen, MM, Brugman, MH et al. (2007). Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Leukemia 21:754-763.
39. Scobie, L, Hector, RD, Grant, L, Bell, M, Nielsen, AA, Meikle, S et al. (2009). A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity. Mol Ther 17:1031-1038.
40. Venkatesan, RN, Treuting, PM, Fuller, ED, Goldsby, RE, Norwood, TH, Gooley, TA et al. (2007). Mutation at the polymerase active site of mouse DNA polymerase delta increases genomic instability and accelerates tumorigenesis. Mol Cell Biol 27:7669-7682.
41. Fern, L, Pallis, M, Ian Carter, G, Seedhouse, C, Russell, N and Byrne, J (2004). Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol 126:63-71.
42. Bhatia, R, Van Heijzen, K, Palmer, A, Komiya, A, Slovak, ML, Chang, KL et al. (2005). Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma. J Clin Oncol 23:6699-6711.
43. Newrzela, S, Al-Ghaili, N, Heinrich, T, Cornils, K, Li, Z, Baum, C et al. Control mechanisms in mature T cell leukemia/lymphoma. Kyoto T Cell Conference 5th International Workshop, 1-4 June 2009.
44. Ginn, SL, Fleming, J, Rowe, PB and Alexander, IE (2003). Promoter interference mediated by the U3 region in early-generation HIV-1-derived lentivirus vectors can influence detection of transgene expression in a cell-type and species-specific manner. Hum Gene Ther 14:1127-1137.
45. Sastry, L, Johnson, T, Hobson, MJ, Smucker, B and Cornetta, K (2002). Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther 9:1155-1162.
46. Lo, M, Bloom, ML, Imada, K, Berg, M, Bollenbacher, JM, Bloom, ET et al. (1999). Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach. Blood 94:3027-3036.
47. Zhang, F, Thornhill, SI, Howe, SJ, Ulaganathan, M, Schambach, A, Sinclair, J et al. (2007). Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood 110:1448-1457.
48. Hu, M, Watson, D, Zhang, GY, Graf, N, Wang, YM, Sartor, M et al. (2008). Long-term cardiac allograft survival across an MHC mismatch after 'pruning' of alloreactive CD4 T cells. J Immunol 180:6593-6603.
49. Walters, G and Alexander, SI (2004). T cell receptor BV repertoires using real time PCR: a comparison of SYBR green and a dual-labelled HuTrec fluorescent probe. J Immunol Methods 294:43-52.
50. Schmidt, M, Schwarzwaelder, K, Bartholomae, C, Zaoui, K, Ball, C, Pilz, I et al. (2007). High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods 4:1051-1057.
51. Lovatt, A, Black, J, Galbraith, D, Doherty, I, Moran, MW, Shepherd, AJ et al. (1999). High throughput detection of retrovirus-associated reverse transcriptase using an improved fluorescent product enhanced reverse transcriptase assay and its comparison to conventional detection methods. J Virol Methods 82:185-200.